I love LaCroix lol. The flavored stuff. Ya know I've followed this company forever, I've said that here before. The CEO is a nut lol. He's like some kind of crazy genius. I think he's almost 87 now. Every year he writes some goofy letter to investors and they are like this rambling diatribe of life in general. It would be like something you or I would write. I'm honestly surprised he hasn't at least hinted at a cannabis infused drink yet. At least say he has one in the works for if/when it gets legalized.
Those of you that know me for years and years know my take on biotech. I Love It! But it goes in cycles and for sure Bio has been crapped on for months. It's tough to point a finger at the problem but a good amount is the FDA being tied up with all Covid all the time. For me as long as the company keeps delivering on the clinical side I stick with them-- so my biggest loser in THE GARDEN is ZYME. I did get a small amount off when it spiked but I am stuck with the rest. Zymeworks' zanidatamab shows encouraging antitumor activity in HER2+ breast cancer patients Dec. 09, 2021 3:58 AM ETZymeworks Inc. (ZYME) Zymeworks(NYSE:ZYME)announcesnew clinical data for zanidatamab in heavily pretreated HER2-positive breast cancer patients at the San Antonio Breast Cancer Symposium taking place in Texas from December 7-10, 2021. 24 breast cancer patients received zanidatamab in combination with either vinorelbine (n=12), capecitabine (n=8), or paclitaxel (n=4). In 22 efficacy-evaluable patients, zanidatamab and chemotherapy resulted in a overall confirmed objective response rate of 36.4% and disease control rate of 86.4%, and the majority of patients experienced a decrease in their tumor size. The median progression-free survival is 7.3 months. Zanidatamab + chemotherapy is well tolerated, with majority of treatment-related adverse events being mild to moderate in severity.
with that in mind lets put QURE back in Play here-- we took some time off and it held up rather well! QURE uniQure N.V. $30.31 0.96(+3.25%) 9:30 AM 12/09/21
Additionally, QURE is working on a number of other gene therapy targets (for example, Parkinson's disease and epilepsy). These treatments are in an earlier stage of development, but also potentially address billion dollar markets. The diagram below shows the prevalence of Huntington's disease in the world.
I thought J Frogg Was A Retailer-- JFrog is the only end-to-end binary solution that bridges the gap between the world of git based tools for source code and the secure delivery of software packages. In a world of fast and secure software big-to-release life cycles, category leaders must coexist and together help organization fulfill their future digital needs. Now on to some product and business highlights. First, for Q3, I would like to tell you about our acquisition of Upswift, an IoT connected device management company that we believe will significantly expand our market. The Upswift team is tasked with extending our DevOps platform reach all the way to the device, allowing for software updates, security and device fleet management from anywhere in the world. This technology innovation will extend our portfolio offering, support new personas and expand our TAMs to serve the DevOps needs to the multibillion-dollar IoT market. In fact, the second largest automobile manufacturer in Europe is already partnering with Upswift and JFrog saying and I quote, "We are using Upswift for our pilot product and looking forward to using Upswift in the future more and more to monitor our fleet of IoT devices in Europe and all over the world. We appreciate the joint venture of Upswift and JFrog, and hopefully, we are able to use other solutions from JFrog in combination with Upswift to get a 360-degree view of our fleet." In the future, the world of CI/CD will be connected to the end devices and the JFrog DevOps platform will connect these 2 words. Amit Ezer. and Eitan Chudnovsky, Co-Founders of Upswift, we welcome you and the team and are already excited to drive customers' initiative forwards. Second, I would like to update you on the impressive progress of last quarter's Vdoo acquisition, that not only included a leading cloud-native security platform, but also exposed us to new personas in the security market and brought a team of experts that are now an integral part of our R&D, product, sales and marketing forces. This technology and team is boosting JFrog's impact and not only driving cross-selling for Xray, our DevSecOps product, but also amplifying our position as thought leaders in the security community. In fact, the JFrog security research team has already uncovered multiple risks in common packages and public repositories. For example, JFrog just recently exposed the vulnerability in a popular open source tool created by 23andMe, a leading provider of DNA and biotechnology services. Their tools are utilized in an estimated 200 public software repositories, affecting potentially thousands of applications and companies. Highly publicized findings such as this one are only the beginning, and we look forward to proactively keeping the developer community made aware of security vulnerability that affect their supply chains.
I'm excited to say that in Q3, JFrog has achieved Iron Bank certification, authorizing JFrog Artifactory and Xray inclusion in the Federal Platform One initiative. With this achievement, JFrog reinforces its commitment to providing DevOps and DevSecOPs solution for its public sector customers and those in highly regulated industries such as finance, health care, energy and transportation. This certification has the potential to open up a very large market of governmental services, contractors and public sector segments that rely on Iron Bank certification to adopt [indiscernible] tools.
yes. just flavored seltzer with a fancy name and can. i think if you have a tastefully decorated apartment and have someone over, you offer them a la croix
FROG JFrog Ltd. 33.79 1.42(+4.39%) 9:38 AM 12/09/21 1 yr MINUS 52%!<------ 6 months DOWN 30%!<------ 1 Month DOWN 14% Bottom put in @ $ 28<------- 5 days PLUS 13%<---------------
On offering someone a la croix... I ask this just for an opinion... straight up no judgements... but there is this trainer where I work out and we have a little banter-- I'm much older but she's got some treads.. Not a young thing... Whatever.. we have a little banter she likes my " style " I always dress up for the gym... Ok so here is the question on the Letch scale and this is really hard to do with the Maxwell trial now concerning Jeffery Epstein.. But I see her giving her clients a little rub now and then and also sometimes heard her complaining about how much air fair costs and on a scale of Letch..0-10 how bad would it be for married me to say ' hey do you do any massage on the side? I have alot of aches and pains.
Nov 8th- JFrog price target raised to $71 from $66 at Needham 11/08 FROG Needham analyst Jack Andrews raised the firm's price target on JFrog to $71 from $66 and keeps a Buy rating on the shares. The company reported a "strong" Q3 result, which may serve a catalyst for a positive inflection in investor sentiment on the stock, the analyst tells investors in a research note. Andrews adds that the first true "beat and raise" in Q3 marks a positive sign that his bullish thesis is playing out and offers evidence of JFrog business acceleration becoming apparent. Wow what hit us! This thing is $33 now.... What is that analysts going to say next? He wil have to reduce his call right? We may be heading into a difficult period like that....